secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prelude Therapeutics Inc (PRLD)
CIK:        0001678660
Form:       8-K
Filed at:   2023-03-15T23:59:59+00:00
Accession:  0000950170-23-007983
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prelude Therapeutics reports FY 2022 net loss of $115.4M; cash runway through Q4 2024
--------------------------------------------------------------------------------

- Net loss of $115.4M ($2.44 per share) vs $111.7M ($2.43 per share) in FY 2021.
- Cash and equivalents of $201.7M as of Dec 31, 2022; runway extended through Q4 2024.
- R&D expenses $92.9M, G&A $30.7M; both up YoY.
- Clinical trial collaboration with BeiGene to evaluate PRT2527 + zanubrutinib in hematologic malignancies.
- Bryant D. Lim appointed Chief Legal Officer, effective Feb 20, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1678660/000095017023007983/0000950170-23-007983-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1678660/000095017023007983/prld-20230315.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-007983

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer